Back to Top
Anti-PD-1 (RMP1-14)
ichorbio's anti-PD-1 (RMP1-14) antibody is cheaper for academia & non-profits and for industry than the equivalent low endotoxin version from Bio X Cell (BE0146).
"In repeated studies we have found ichorbio's RMP1-14 to be more efficacious than the same clone from Bio X Cell"
Leading Immuno-Oncology CRO
35%
cheaper for
academia
58%
cheaper for
industry
RMP1-14
-
-
-
Murinized anti-Mouse PD-1 (RMP1-14) Recombinant Antibody$600.00 - $4,500.00
Key Benefits
Potential for clearer results in early-stage tumor growth studies- Opportunity to explore impact of lower endotoxin levels
- Supports the 3Rs principle in animal research
- Viable alternative for diversifying experimental approaches
What Researchers Are Saying
Our comparative study has shown interesting trends for ICH1132, particularly in the early stages of tumor growth inhibition. While the differences weren't maintained throughout the entire study period, the consistent trend towards slightly higher efficacy is noteworthy and warrants further exploration in various research settings."
Dr. Sarah Martinez, Lead Researcher
FAQ
What is RMP1-14?
RMP1-14 is a clone name for a specific rat anti-mouse PD-1 antibody. The original hybridoma was generated by immunizing Sprague Dawley rats with mouse PD-1-transfected BHK cells. A P3U1 myeloma was used as the fusion partner.
Who created RMP1-14?
It was developed by Professor Hideo Yagita at the Juntendo University School of Medicine.
What was the first journal article that cited RMP1-14?
Authors: Yamazaki et al.
Journal Title: Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
Journal: J Immunol.
Additonal Info: 2005 Aug 1;175(3):1586-92 PMID:16034097
The article above describes the generation and initial characterisation of the RMP1-14 hybridoma.
Blocking Functionality
Like the J43 clone, RMP1-14 has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1.
Citations
A total of 470 articles have been published over the last three years citing RMP1-14, with scientists from 300 organisations in 32 countries contributing to the research. The top authors publishing articles using RMP1-14 in the last three years are show in Table 1 below.
Image 1: The top 10 most prolific authors citing RMP1-14
A breakdown of the main locations of the authors are shown in Image 2 below. In Image 3 we show the main institutes that cite work using RMP1-14.
Top institutions citing RMP1-14
Images kindly provided by OE1.8
Latest Research Articles Using RMP1-14
- Tristan Rupp, Porsolt SAS. Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response.
- Jianxin Wang, John Hopkins University School of Medicine. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.
- Atsushi Enomoto, Nagoya University. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.
- Robert Sobol, Multivir. Tumor suppressor immune gene therapy to reverse immunotherapy resistance.
Who Bought This Also Bought
